Back to the main list of congress faculty

BIOGRAPHY   Robert C. Green, MD, MPH Professor of Neurology, Genetics and Epidemiology Boston University Schools of Medicine and Public Health Boston, Massachusetts Robert C. Green, MD, MPH, is Professor of Neurology and Medicine (Genetics) at the Boston University School of Medicine and Professor of Epidemiology at the Boston University School of Public Health. Dr Green is also Associate Director of the NIH Alzheimer’s Disease Center at Boston University School of Medicine. Dr Green earned his MD at the University of Virginia Medical School in Charlottesville, Virginia, and his MPH in epidemiology at the Emory University School of Public Health in Atlanta, Georgia. Dr Green is the recipient of several honors and awards, including the William B. Lennox Postdoctoral Research Fellowship. He has written over 100 published pieces, including articles, reviews, book chapters, and abstracts. Dr Green also serves as a reviewer for the New England Journal of Medicine, the Journal of the American Medical Association, Neurology, Alzheimer’s Disease, and the Journal of Geriatric Psychiatry and Neurology, among others. Dr Green’s research interests are in the genetic epidemiology of Alzheimer’s disease and in early and preclinical detection, treatment, and prevention of Alzheimer’s disease. He is a co-Principal Investigator on Boston University’s NIH-funded Multi-Institutional Research in Alzheimer’s Genetic Epidemiology (MIRAGE) Study, a consultant on the NIH-funded Cache County Memory and Aging Study, and is the Boston site director of the NIH-funded Alzheimer’s Disease Anti-Inflammatory Prevention Trial (ADAPT) Study, one of the first large-scale intervention trials to prevent the development of Alzheimer’s disease in at-risk family members. Dr Green is also Principal Investigator and Director of the Risk Evaluation and Education for Alzheimer’s Disease (REVEAL) Study, a new multi-center project funded by the National Human Genome Research Institute and the National Institute on Aging to develop genetic risk assessment strategies for individuals at risk for Alzheimer’s disease.